REN001 - Phase 1b Clinical Trial
REN001 - Phase 1b Clinical Trial
About This Event
Phase 1b data due 1Q 2022.
Why This Event Matters
Regulatory milestones can be important for biotech and pharmaceutical names because decisions may affect timelines, labeling, and commercial prospects. Outcomes are uncertain until confirmed by the company or agency materials; this listing is informational. The date shown is March 31, 2022 (America/New_York).
Source summary: Phase 1b data due 1Q 2022.
This listing is associated with RPHM. Market participants may watch these names around the event window for volatility or news flow.
Frequently Asked Questions
- What is REN001 - Phase 1b Clinical Trial?
- It is a stock market catalyst entry on Catacal—an event or release investors and traders may monitor. Details are summarized from the cited source and may be updated over time.
- When is REN001 - Phase 1b Clinical Trial?
- The calendar shows Mar 31, 2022 (America/New_York). Verify the exact time and any changes using the source link when planning around the event.
- Why does REN001 - Phase 1b Clinical Trial matter for investors?
- Regulatory outcomes can change timelines and risk profiles for drug and device developers.
- Which stocks or sectors could be affected?
- Symbols linked to this listing include RPHM; other names in the same industry group may also move with related news.
- How is this event categorized?
- Catacal groups this entry under "FDA Approval" for navigation. Categories help you find comparable catalysts and build a week-by-week watchlist.
Track Market-Moving Events
Monitor earnings, economic releases, lockups, conferences, and other catalysts that impact stocks.
View Catalyst CalendarComprehensive Calendar
Track earnings, product launches, FDA approvals, economic events, and more.
Impact Ratings
Know which catalysts have the greatest potential to impact stock prices.
Never Miss an Event
Get alerts and reminders so you're always prepared for market-moving events.
View Catalyst Calendar
Track upcoming market events